This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bremnes, R. M. Articles by Franklin, W. A. Search for Related Content PubMed PubMed Citation Articles by Bremnes, R. M. Articles by Franklin, W. A. Social Bookmarking                            What's this?

High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non–Small-Cell Lung Cancer

From the Departments of Pathology and Preventive Medicine, and Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO; Department of Pathology, Johns Hopkins Medical Center, Baltimore, MD, and Department of Oncology, University Hospital of Tromsø, Tromsø, Norway.

Address reprint requests to Roy M. Bremnes, MD, PhD, Department of Oncology, University Hospital of Tromsø, N-9038 Tromsø, Norway; email: roy.bremnes{at}rito.no

PURPOSE: E-cadherin (E-cad) and its associated intracellular molecules, catenins, are critical for intercellular epithelial adhesion and are often expressed in non–small-cell lung carcinomas (NSCLCs). We constructed tissue microarrays (TMAs) to investigate the expression of cadherins and catenins and their prognostic significance in NSCLC.

PATIENTS AND METHODS: Tumor tissue samples from 193 patients with stages I to III NSCLC were obtained from the University of Colorado Cancer Center and Johns Hopkins Medical Institutions. Viable tumor was sampled in triplicate for the TMAs, and slides were stained by immunohistochemistry with antibodies against E-cad, N-cadherin, alpha ()-, beta (ß)-, and gamma ()-catenin, p120, p27, and adenomatous polyposis coli (APC) gene product. Clinical data were collected by the tumor registries. Patients were followed for a median period of 51 months (range, 18 to 100 months).

RESULTS: Absent or severely reduced membranous expression for E-cad, -, ß-, and -catenin, and p120 were observed in 10%, 17%, 8%, 31%, and 61% of the cases, respectively. Tumor cell dedifferentiation correlated with reduced expression for E-cad, ß-catenin, -catenin, and p120 in squamous cell carcinomas but not in adenocarcinomas. There was an inverse correlation between nodal metastasis and expression of E-cad and -catenin. Besides the traditional clinical prognostic variables, E-cad and -, ß-, and -catenin expression were of positive prognostic value in univariate survival analyses. In multivariate analysis, E-cad expression was the only independent prognostic factor for survival in addition to age, node status, tumor status, and pathologic surgical margins.

CONCLUSION: Reduced expression of E-cad and catenins is associated with tumor cell dedifferentiation, local invasion, regional metastasis, and reduced survival in NSCLC. E-cad is an independent prognostic factor for NSCLC survival.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H.-W. Chen, J.-Y. Lee, J.-Y. Huang, C.-C. Wang, W.-J. Chen, S.-F. Su, C.-W. Huang, C.-C. Ho, J. J.W. Chen, M.-F. Tsai, et al. Curcumin Inhibits Lung Cancer Cell Invasion and Metastasis through the Tumor Suppressor HLJ1 Cancer Res., September 15, 2008; 68(18): 7428 - 7438. [Abstract] [Full Text] [PDF]

				Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 95 - 104. [Abstract] [Full Text] [PDF]

				T. Donnem, S. Al-Saad, K. Al-Shibli, M. P. Delghandi, M. Persson, M. N. Nilsen, L.-T. Busund, and R. M. Bremnes Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non Small Cell Lung Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6649 - 6657. [Abstract] [Full Text] [PDF]

				Y. Chung, A. K. Y. Lam, J. M. Luk, S. Law, K.-W. Chan, P.-Y. Lee, and J. Wong Altered E-Cadherin Expression and p120 Catenin Localization in Esophageal Squamous Cell Carcinoma Ann. Surg. Oncol., November 1, 2007; 14(11): 3260 - 3267. [Abstract] [Full Text] [PDF]

				N. Fujii, L. You, Z. Xu, K. Uematsu, J. Shan, B. He, I. Mikami, L. R. Edmondson, G. Neale, J. Zheng, et al. An Antagonist of Dishevelled Protein-Protein Interaction Suppresses {beta}-Catenin-Dependent Tumor Cell Growth Cancer Res., January 15, 2007; 67(2): 573 - 579. [Abstract] [Full Text] [PDF]

				L. W. Wattenberg An interlocker concept of carcinogenesis. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1425 - 1426. [Abstract] [Full Text] [PDF]

				C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]

				M. Dohadwala, S.-C. Yang, J. Luo, S. Sharma, R. K. Batra, M. Huang, Y. Lin, L. Goodglick, K. Krysan, M. C. Fishbein, et al. Cyclooxygenase-2-Dependent Regulation of E-Cadherin: Prostaglandin E2 Induces Transcriptional Repressors ZEB1 and Snail in Non-Small Cell Lung Cancer. Cancer Res., May 15, 2006; 66(10): 5338 - 5345. [Abstract] [Full Text] [PDF]

				K A Voutilainen, M A Anttila, S M Sillanpaa, K M Ropponen, S V Saarikoski, M T Juhola, and V-M Kosma Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer J. Clin. Pathol., May 1, 2006; 59(5): 460 - 467. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]

				S. E. Witta, R. M. Gemmill, F. R. Hirsch, C. D. Coldren, K. Hedman, L. Ravdel, B. Helfrich, R. Dziadziuszko, D. C. Chan, M. Sugita, et al. Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines Cancer Res., January 15, 2006; 66(2): 944 - 950. [Abstract] [Full Text] [PDF]

				R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients Clin. Cancer Res., December 15, 2005; 11(24): 8686 - 8698. [Abstract] [Full Text] [PDF]

				S. Thomson, E. Buck, F. Petti, G. Griffin, E. Brown, N. Ramnarine, K. K. Iwata, N. Gibson, and J. D. Haley Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non-Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition Cancer Res., October 15, 2005; 65(20): 9455 - 9462. [Abstract] [Full Text] [PDF]

				S. M. Lippman, N. Gibson, K. Subbaramaiah, and A. J. Dannenberg Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways Clin. Cancer Res., September 1, 2005; 11(17): 6097 - 6099. [Full Text] [PDF]

				Z. Yu, P. M. Weinberger, E. Provost, B. G. Haffty, C. Sasaki, J. Joe, R.L. Camp, D.L. Rimm, and A. Psyrri {beta}-Catenin Functions Mainly as an Adhesion Molecule in Patients with Squamous Cell Cancer of the Head and Neck Clin. Cancer Res., April 1, 2005; 11(7): 2471 - 2477. [Abstract] [Full Text] [PDF]

				I. S. Aljada, N. Ramnath, K. Donohue, S. Harvey, J. J. Brooks, S. M. Wiseman, T. Khoury, G. Loewen, H. K. Slocum, T. M. Anderson, et al. Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3218 - 3229. [Abstract] [Full Text] [PDF]

				J. Fukuoka, T. Fujii, J. H. Shih, T. Dracheva, D. Meerzaman, A. Player, K. Hong, S. Settnek, A. Gupta, K. Buetow, et al. Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2004; 10(13): 4314 - 4324. [Abstract] [Full Text] [PDF]

				I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1242 - 1252. [Abstract] [Full Text] [PDF]

				T. Ohira, R. M. Gemmill, K. Ferguson, S. Kusy, J. Roche, E. Brambilla, C. Zeng, A. Baron, L. Bemis, P. Erickson, et al. WNT7a induces E-cadherin in lung cancer cells PNAS, September 2, 2003; 100(18): 10429 - 10434. [Abstract] [Full Text] [PDF]

				T. Shimamura, M. Sakamoto, Y. Ino, Y. Sato, K. Shimada, T. Kosuge, H. Sekihara, and S. Hirohashi Dysadherin Overexpression in Pancreatic Ductal Adenocarcinoma Reflects Tumor Aggressiveness: Relationship to E-Cadherin Expression J. Clin. Oncol., February 15, 2003; 21(4): 659 - 667. [Abstract] [Full Text] [PDF]

				Z.-y. Huang, Y. Wu, N. Hedrick, and D. H. Gutmann T-Cadherin-Mediated Cell Growth Regulation Involves G2 Phase Arrest and Requires p21CIP1/WAF1 Expression Mol. Cell. Biol., January 15, 2003; 23(2): 566 - 578. [Abstract] [Full Text] [PDF]

				T. A. Plunkett and P. A. Ellis CEACAM1: A Marker With a Difference or More of the Same? J. Clin. Oncol., November 1, 2002; 20(21): 4273 - 4275. [Full Text] [PDF]